USANA Health Sciences (NYSE:USNA) Releases FY 2024 Earnings Guidance

USANA Health Sciences (NYSE:USNA) updated its FY 2024 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 2.400-3.000 for the period, compared to the consensus estimate of 2.720. The company issued revenue guidance of $850.0 million-$920.0 million, compared to the consensus revenue estimate of $889.8 million.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on USNA shares. DA Davidson dropped their price target on shares of USANA Health Sciences from $53.00 to $48.00 and set a neutral rating for the company in a research report on Thursday, February 22nd. StockNews.com upgraded shares of USANA Health Sciences from a buy rating to a strong-buy rating in a research report on Friday, January 12th.

USANA Health Sciences Stock Down 3.4 %

Shares of NYSE USNA traded down $1.48 during midday trading on Tuesday, reaching $41.50. 104,538 shares of the company were exchanged, compared to its average volume of 80,488. The stock’s 50-day moving average price is $46.94 and its 200-day moving average price is $48.56. The stock has a market cap of $798.46 million, a P/E ratio of 12.88, a PEG ratio of 1.33 and a beta of 0.91. USANA Health Sciences has a one year low of $41.45 and a one year high of $69.60.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.52 by $0.35. USANA Health Sciences had a net margin of 6.93% and a return on equity of 13.49%. The company had revenue of $221.08 million for the quarter, compared to analysts’ expectations of $206.70 million. On average, equities research analysts anticipate that USANA Health Sciences will post 2.73 EPS for the current year.

Insider Activity

In other news, Chairman Kevin Guest sold 11,011 shares of the company’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $49.00, for a total transaction of $539,539.00. Following the transaction, the chairman now owns 10,491 shares in the company, valued at $514,059. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Chairman Kevin Guest sold 11,011 shares of the company’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $49.00, for a total value of $539,539.00. Following the sale, the chairman now owns 10,491 shares in the company, valued at approximately $514,059. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Robert A. Sinnott sold 3,945 shares of the company’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $46.55, for a total transaction of $183,639.75. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 24,807 shares of company stock worth $1,200,791. Company insiders own 0.33% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.